Patent Protection in Russia: Implications of USPTO Actions and U.S. Sanctions for Safeguarding IP Rights
Recording of a 90-minute premium CLE video webinar with Q&A
This CLE webinar will review the implications of U.S sanctions on Russia and recent U.S. Patent and Trademark Office (USPTO) actions for patent owners and applicants. The panel will also address the steps that Russia has taken in response and what they may mean for U.S. companies holding patents in Russia. Finally, the panel will discuss what U.S. companies might do to protect their patents and minimize the risk of infringement.
- U.S. sanctions on Russia
- Current state of the relationship between the USPTO and Rospatent and other relevant patent offices
- Russian response and implications for U.S. companies holding patents in Russia
- What U.S. companies might do to protect their patents and minimize the risk of infringement
- Best practices
The panel will review these and other key issues:
- What do the U.S. sanctions mean for maintaining patents in Russia?
- What are the implications of the USPTO breaking ties with the Russian Patent Office (Rospatent) and the Eurasian Patent Office?
- What steps can U.S. companies and their counsel take to minimize the risks of infringement?
Mark P. Mathison, P.E.
Kilpatrick Townsend & Stockton
Mr. Mathison builds patent assets for businesses and universities through patent prosecution. His practice spans all... | Read More
Mr. Mathison builds patent assets for businesses and universities through patent prosecution. His practice spans all manner of electronics and software and mechanical patents, including flourishing expertise in electronic medical devices. Mr. Mathison counsels startups, Fortune 100 companies, high-net worth individuals, and small and medium sized businesses looking to build something new and protect it against other market players. Those looking for real business-sense protection of inventive concepts, whether in pursuing patents, fortifying trade secrets, or technological protection, find a trusted and articulate counselor in Mr. Mathison.Close
Sean D. Solberg
Fredrikson & Byron
Mr. Solberg works with businesses and entities ranging from startups and universities to Fortune 500 companies to... | Read More
Mr. Solberg works with businesses and entities ranging from startups and universities to Fortune 500 companies to protect their technologies through patent prosecution, enforcement and competitive patent analyses in a variety of industries, including medical device, biotech and agriculture. He manages and implements strategies for both emerging and significant patent and application portfolios, drafts and prosecutes patent applications in various technologies, performs due diligence investigations of IP portfolios in M&A deals, evaluates the validity and enforceability of patents, and advises on infringement issues. He also drafts and negotiates various technology agreements, such as licenses, assignments and agreements related to research, collaboration and consulting. In addition to his expertise in patent prosecution, IP transactions, opinions and due diligence, Mr. Solberg has experience in complex IP litigation, providing support and drafting briefs in conjunction with IP litigators. He is a registered patent attorney, licensed to practice before the United States Patent and Trademark Office.Close
E. Jay Wilusz
Senior Corporate Patent Counsel
Bristol Myers Squibb
Prior to his position at BMS, Mr. Wilusz established a patent law firm in Washington State. His clients included... | Read More
Prior to his position at BMS, Mr. Wilusz established a patent law firm in Washington State. His clients included academic institutions and large and small companies. He procures and defends intellectual property rights and negotiates transactions and acquisitions for biopharma interests. Those interests include small molecule, biotech, and cellular therapies, AI and ML initiatives for drug discovery, clinical innovations, and patient disease monitoring tools. Mr. Wilusz has collaborated to optimize exclusivity for more than 100 products with combined annual sales of over 80 billion dollars for his clients. He has secured IP rights for assets that span drug discovery, clinical development, and patient centric innovations. Mr. Wilusz has previously held roles as Senior VP of IP and Licensing at Makai Biotechnology, Life Cycle Management Lead at Sanofi, and VP of IP at Novartis. He is a USPTO registered patent attorney.Close